{"id":"br-td-1001","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug targets neurotrophic signaling pathways implicated in neurodegenerative diseases. By modulating TrkA (tropomyosin receptor kinase A) and p75 neurotrophin receptor, BR-TD-1001 aims to reduce neuroinflammation and promote neuroprotection, potentially slowing disease progression in conditions characterized by neuronal loss.","oneSentence":"BR-TD-1001 is a dual-acting compound that modulates both TrkA and p75NTR signaling pathways involved in neuroinflammation and neurodegeneration.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:42:17.223Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"},{"name":"Mild cognitive impairment"}]},"trialDetails":[{"nctId":"NCT04618939","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children","status":"COMPLETED","sponsor":"Boryung Biopharma Co., Ltd.","startDate":"2016-10-20","conditions":"Diphtheria, Tetanus","enrollment":218}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BR-TD-1001","genericName":"BR-TD-1001","companyName":"Boryung Biopharma Co., Ltd.","companyId":"boryung-biopharma-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"BR-TD-1001 is a vaccine intended to prevent Diphtheria and Tetanus, as indicated by ClinicalTrials.gov. It is administered intramuscularly to healthy children in a double-blind, randomized Phase III study to evaluate its immunogenicity and safety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}